Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2016, Article ID 9692568, 5 pages
http://dx.doi.org/10.1155/2016/9692568
Case Report

Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery

1Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536, USA
2Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY 40536, USA
3Department of Pharmacy Services, South Pointe Hospital, Cleveland Clinic, Cleveland, OH 44195, USA

Received 13 February 2016; Revised 22 April 2016; Accepted 28 April 2016

Academic Editor: Petros Kopterides

Copyright © 2016 Sara E. Parli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. E. Baetz and S. A. Spinler, “Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases,” Pharmacotherapy, vol. 28, no. 11, pp. 1354–1373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Stangier, “Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate,” Clinical Pharmacokinetics, vol. 47, no. 5, pp. 285–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. E. Winter, Basic Clinical Pharmacokinetics, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 4th edition, 2004.
  4. J. Bouchard, M. Ghannoum, A. Bernier-Jean et al., “Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran,” Clinical Toxicology, vol. 53, no. 3, pp. 156–163, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Singh, T. T. Maw, B. L. Henry et al., “Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 9, pp. 1533–1539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Stangier, K. Rathgen, H. Sthle, and D. Mazur, “Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study,” Clinical Pharmacokinetics, vol. 49, no. 4, pp. 259–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. N. Chang, W. E. Dager, and A. I. Chin, “Removal of dabigatran by hemodialysis,” American Journal of Kidney Diseases, vol. 61, no. 3, pp. 487–489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Khadzhynov, F. Wagner, S. Formella et al., “Effective elimination of dabigatran by haemodialysis: a phase I single-centre study in patients with end-stage renal disease,” Thrombosis and Haemostasis, vol. 109, no. 4, pp. 596–605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Idarucizumab, Boehringr Ingelheim Pharmaceuticals, Ridgefield, Conn, USA, 2015.
  10. T. E. Warkentin, P. Margetts, S. J. Connolly, A. Lamy, C. Ricci, and J. W. Eikelboom, “Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding,” Blood, vol. 119, no. 9, pp. 2172–2174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Wolzt, M. Levi, T. C. Sarich et al., “Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers,” Thrombosis and Haemostasis, vol. 91, no. 6, pp. 1090–1096, 2004. View at Google Scholar · View at Scopus
  12. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. T.-L. Khoo, C. Weatherburn, G. Kershaw, C. J. Reddel, J. Curnow, and S. Dunkley, “The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran,” International Journal of Laboratory Hematology, vol. 35, no. 2, pp. 222–224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. W. E. Dager, R. C. Gosselin, and A. J. Roberts, “Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity,” Critical Care Medicine, vol. 41, no. 5, pp. e42–e46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. C. V. Pollack, P. A. Reilly, J. Eikelboom et al., “Idarucizumab for dabigatran reversal,” The New England Journal of Medicine, vol. 373, no. 6, pp. 511–520, 2015. View at Publisher · View at Google Scholar · View at Scopus